Table 3. Relationship between the changes in %FMD and other metabolic parameters pre- and post-treatment with sitagliptin or glimepiride.
| Variables | r | P value for the Spearman’s rank-correction | r | P value for the Spearman’s rank-correction |
|---|---|---|---|---|
| Medication | Sitagliptin | Glimepiride | ||
| BMI | 0.189 | 0.238 | -0.056 | 0.701 |
| HbA1c | 0.008 | 0.962 | 0.073 | 0.617 |
| SBP | -0.273 | 0.084 | -0.103 | 0.481 |
| DBP | -0.165 | 0.304 | -0.113 | 0.439 |
| HDL-cholesterol | -0.067 | 0.677 | 0.035 | 0.809 |
| LDL-cholesterol | -0.086 | 0.618 | 0.061 | 0.679 |
FMD, flow-mediated dilation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.